ALNYLAM PHARMACEUTICALS, INC. (ALNY) Net margin 2016–2025
ALNYLAM PHARMACEUTICALS, INC. (ALNY) net profit margin by fiscal year — reported net income divided by reported revenue.
8.4%FY2025 · since FY2016: -869.6% → 8.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 8.4% | +20.8 pp |
| FY2024 | -12.4% | +11.7 pp |
| FY2023 | -24.1% | +85.0 pp |
| FY2022 | -109.0% | -8.0 pp |
| FY2021 | -101.0% | +73.1 pp |
| FY2020 | -174.1% | +229.1 pp |
| FY2019 | -403.2% | +613.3 pp |
| FY2018 | -1016.6% | -470.6 pp |
| FY2017 | -545.9% | +323.7 pp |
| FY2016 | -869.6% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More ALNY financial trends
ALNY RevenueALNY Net incomeALNY Gross profitALNY Gross marginALNY Operating incomeALNY Operating marginALNY Operating cash flowALNY Free cash flowALNY Capital expendituresALNY Return on equityALNY Stock buybacksALNY Dividends paidALNY Total assetsALNY Total liabilitiesALNY Shareholders’ equityALNY overview →